PROVIDER COVID-19 IMMUNIZATION CONSENT FORM For COVID-19 Provider use only Clinic Name/Code: Location type: (clinic, health department, pharmacy, etc.,) Address: City: County: State: Zip Code: Date of Service: Person Receiving Vaccine: (Legal) First Name: MI: Last Name: Date of Birth: MEDICAL HISTORY: Complete the following questions for the individual receiving the vaccine. If you answer "YES" you may not be able to receive the COVID-19 vaccine. If YES refer to following websites at www.PfizerMedInfo.com. Moderna www.modernatx.com. Janssen www.janssencovid19vaccine.com. Refer to Pre-vaccination Checklist for COVID-19 vaccines to clarify questions: *YESNO www.cdc.gov/vaccines/covid-19/downloads/pre-vaccination-screening-form.pdf. Have you had a previous COVID-19 vaccine? If yes, what type and date? Do you have a fever today? Are you sick today? Do you have COVID-19 infection and are currently in isolation? Are you currently in quarantine for known exposure to COVID-19? Have you ever had an allergic reaction to a COVID-19 vaccine or a COVID-19 vaccine component (including polyethylene glycol [PEG], which is found in some medications, or laxatives, and preparations for colonoscopy; or polysorbate, which is found in some vaccines, coated tablets, or IV steroids)? Have you ever had an allergic reaction that caused hives, swelling, respiratory distress (including wheezing) or anaphylaxis to a vaccine other than COVID-19 vaccine or an injectable medication that required treatment with epinephrine (EpiPen) or treatment at a hospital? Severe reaction or anaphylaxis to food, pet, venom, environmental, or oral medication allergies are not contraindications or precautions to vaccination with any COVID-19 vaccine. Do you have a bleeding disorder or are you taking a blood thinner? Have you received a hematopoietic cell transplant (HCT) or CAR-T-cell therapy since receiving COVID-19 vaccine? You should be revaccinated with a primary vaccine series at least 12 weeks after transplant or CAR-T-cell therapy. Did you develop myocarditis or pericarditis after the first dose of COVID-19 vaccine? You should not receive a subsequent dose of any COVID-19 vaccine. If you have developed myocarditis or pericarditis unrelated to an mRNA COVID vaccination, may receive COVID-19 vaccine after the episode has completely resolved. Are you immunocompromised? Do you have a condition that weakens your immune system? Are you receiving any immunosuppressive therapy? You are eligible to receive any FDA-authorized or FDA-approved COVID-19 vaccine unless you have a contraindication for some other reason. However, you will need special counseling about the vaccine. Have you had history of Heparin-Induced Thrombocytopenia (HIT) or Thrombosis with Thrombocytopenia Syndrome (TTS)? You may receive Pfizer-BioNTech or Moderna COVID-19 vaccine. Have you had history of Thrombosis with Thrombocytopenia Syndrome (TTS) following Janssen or any other adenovirus-vector (AstraZeneca) COVID-19 vaccine? Those who developed TTS after the initial Janssen vaccine should not receive a Janssen or any other adenovirus-vector COVID-19 vaccine booster dose. You may receive a mRNA COVID-19 vaccine. Have you received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment or for post-exposure prophylaxis (PEP)? Defer vaccination 90 days after treatment and defer 30 days after PEP. Have you had Multisystem Inflammatory Syndrome (MIS)? Defer vaccination for at least 90 days. The decision for COVID-19 vaccination should be between the patient, their guardian, clinical team, or a specialist. Have you had history of Guillain-Barre Syndrome (GBS)? People with a history of GBS can receive any FDA-authorized or approved COVID-19 vaccine. People who had GBS after receiving Janssen vaccine should receive a Pfizer-BioNTech or Moderna COVID-19 vaccine booster at least 8 weeks after the Janssen dose. NOTE: CDC has made a clinical preference for persons 18 years and older to receive an mRNA COVID-19 vaccine over Janssen COVID-19 vaccine. Patients who cannot or unwilling to receive an mRNA vaccine will be able to access Janssen COVID-19 vaccine. The Janssen Fact Sheet must be provided and explained to the recipient or parent/legal representative about the risks and benefits and address any questions or concerns that the recipient or parent/legal representative may have prior to the vaccination. Recipients of Janssen COVID-19 vaccine should seek immediate medical attention if they develop shortness of breath, chest pain, leg pain or swelling, persistent abdominal pain, severe or persistent headaches or blurred vision, easy bleeding beyond the vaccination site within 30 days of a Janssen vaccination. NOTE: A second dose of COVID-19 vaccine may be due in 21 days or 28 days after initial vaccine. Refer to your COVID-19 vaccination record card for proof of initial vaccine date and for second dose due date. Contact your vaccination provider, PCP, or your ADH Local Health

2. RELEASE AND ASSIGNMENT: Please read the section on the reverse side of this form. The Providers Privacy Notice is available at the clinic site or accompanies this form. Then sign in the box at right.

Unit in 21 days or 28 days for more information.

Please sign here

Date			
Date			

re most current Janssen COVID-19 Fact Sheet to vaccine recipient ns with the vaccine recipient prior to vaccination with Janssen	nt of providing the	dressing any que	nitial Here: ☐ Vaccine Administrator explaining the risk and benefits) and ac				
tracinion eniocity of tend 2 tool 01 (IVO) according to the day tool of the day to the d	/	/	Signature and Title of Vaccine. Date Vaccine Administered:				
, $JSN=Janssen$, $NVX=Novavax$, $MSD=Merck$ = RL , $Left Leg = LL$, $Right Arm = RA$, $Left Arm = LA$	S=AstraZeneca LD, Right Leg	=Moderna, AS = biotleft fled	MFG Codes: PFR=Pfizer, MOD: Site Codes: Right Deltoid = RD.				
			МІ □				
Lot Number	MFG Code	Dosage mL	Route Site Code				
Refrigerated COVID-19 Vaccine AstraZeneca Janssen (Johnson & Johnson) Novavax-Matrix-M1 Other COVID-19 Vaccine	Frozen COVID-19 Vaccine Modema		Ultra-cold COVID-19 Vaccine Pfizer-BioNTech (Purple Cap) Pfizer-BioNTech (Orange Cap) Pfizer-BioNTech (Gray Cap)				
g flu vaccine. COVID-19 vaccines and other vaccines may be administration of COVID-19 vaccines and other vaccines during the after COVID-19 vaccination. Refer to the Pre-vaccination Checklist gov/vaccines/covid-19/downloads/pre-vaccination-screening-ions Summary Document for Interim Clinical Considerations for Use	vaccines, including es simultaneous ; ny time before or estions:www.cdc inical Consideratinical Considerat	cines and other y	administered without regard to tin same visit. Other vaccines can also b for COVID-19 vaccines to clarify me				
			Policy Holder's Employer Name:				
Email Address:		/	Policy Holder Date of Birth:				
	Last Name:	:IM	(Legal) First Name:				
	:N	NEORMATION	ВЕОПІВЕ ВОГІСА НОГ DEB І				
Member ID/Policy #:							
			Insurance Company Name:				
Medicare Number:							
☐ Medicaid/ARKids Number:							
Patient's Relationship to Insurance Policy Holder: Self Spouse Child Other							
INSURANCE STATUS (Check appropriate box):							
Ethnicity:							
Race: Asian Black/African American Mative American /Alaska Mative Mative Mative Dative Hawaiian/Other Pacific Islander White Other							
City: State: Zip Code:							
Apt. No.	ZoH.O.4		Street Address:				
Male Female Phone #:	Gender:		Date of Birth:				
MI: Last Name:			PATIENT INFORMATION:				
ded in (WeblZ) Arkansas Immunization Information System. surrance claim(s). 9 Provider.	COVID-19 vaccind of visit your Local I dividual named belo provider's Privacy nation will be includy to process my in by to this COVID-19 to this COVID-19 is rendered until I rest	or Sheet for Pfizer by veet for Pfizer by veets a copy of the information necessatical benefits directly by veets by vee	To read the Vaccine Recipient EUA Fac https://www.cdc.gov/vaccines/covid-1 • I give consent to this COVID-19 provi • I hereby acknowledge that I have revie				